Hope for stargardt patients: phase 3 drug trial aims to halt vision decline

NCT ID NCT07419334

First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 9 times

Summary

This study tests an investigational drug called gildeuretinol acetate (ALK 001) in 230 people aged 8 to 45 with Stargardt disease, an inherited condition that causes progressive vision loss. The goal is to see if the drug can slow the growth of damage in the retina and help preserve eyesight over 24 months. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor the doctors know who gets which.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Associated Retina Consultants

    RECRUITING

    Phoenix, Arizona, 85020, United States

    Contact

    Contact Email: •••••@•••••

  • Erie Retina Research

    RECRUITING

    Erie, Pennsylvania, 16505, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vitreo Retinal Associates

    NOT_YET_RECRUITING

    Gainesville, Florida, 32607, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.